GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP, NORTH AMERICA (GARDP NA)

Lobbying Spend

—

Filings

Firms Hired

Active Period

2021–2022

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2022	—	1	1
2021	—	2	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
FAEGRE DRINKER BIDDLE & REATH LLP	—	3

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
No government targets were reported in these filings.

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	2

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 3932117th Congress

PASTEUR Act of 2021

Cited source text and reported amounts

Antibiotic research and development; CURES 2.0; S.2076, H.R. 3932 - PASTEUR Act.

Client expense: — · Firm income: —

Matched citations: H.R. 3932

S. 2076117th Congress

PASTEUR Act of 2021

Cited source text and reported amounts

Antibiotic research and development; CURES 2.0; S.2076, H.R. 3932 - PASTEUR Act.

Client expense: — · Firm income: —

Matched citations: S.2076

GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP, NORTH AMERICA (GARDP NA) — Lobbying Disclosure | Poliscope